Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03121677 · ClinicalTrials.gov registry record · Phase 1
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03121677 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 4 participants.
The verdict
NCT03121677, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Follicular lymphoma (FL) has a number of effective standard of care therapies; however, FL is not currently considered curable. Therefore, designing well tolerated therapies without cumulative and long-term toxicity is critical. This is a pilot safety and feasibility study that combines a personalized tumor vaccine with nivolumab for the treatment of FL. Patients who demonstrate progression on this study may be treated with rituximab (or another monoclonal antibody against CD20) in addition to vaccine therapy with nivolumab at the discretion of treating physician if clinically indicated.
Interventions
- BIOLOGICAL Nivolumab
- PROCEDURE Leukapheresis
- DRUG Poly ICLC
- PROCEDURE Peripheral blood draws
- BIOLOGICAL Personalized tumor vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2023-08-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03121677
The ClinicalTrials.gov registry entry for NCT03121677 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT03121677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03121677 about?
NCT03121677 is a clinical study titled "Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma". Follicular lymphoma (FL) has a number of effective standard of care therapies; however, FL is not currently considered curable. Therefore, designing well tolerated therapies without cumulative and long-term toxicity is critical. This is a pilot safety and feasibility study that combines a personaliz...
What is the current status of trial NCT03121677?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2018-10-16. Estimated completion is 2023-08-07.
What interventions are being tested in trial NCT03121677?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Leukapheresis (PROCEDURE), Poly ICLC (DRUG), Peripheral blood draws (PROCEDURE), Personalized tumor vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03121677?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.